tarceva/avastin

IN ADDITION TO THE ABOVE

“21. EGFR/VEGF ( panitumumab+ bevacizumab ; erlotinib+ bevacizumab. And Sorafenib + Erlotinib )
A recent case report of dual therapy with panitumumab and bevacizumab in a patient with widely metastatic GBC unfit for any cytotoxic therapy demonstrated a significant PR and improvement in performance status for 7 months (Riley and Carloss, 2011). A phase II study of 49 evaluable patients with chemotherapy-naïve aBTC investigated EGFR/VEGF inhibition with erlotinib and bevacizumab (Lubner et al., 2010). Six confirmed PRs were noted with a median duration of response being 8.4 months in those patients. Overall mTTP was 4.4 months and mOS was 9.9 months. Exploratory analysis of EGFR mutational status showed that those with EGFR truncation variant III or those with KRAS mutation suggested a less likely response to erlotinib; serum VEGF expression was not noted to change from baseline between responders and nonresponders. Recently, the SWOG 0941 trial enrolled 30 evaluable patients to receive first-line therapy with daily sorafenib and erlotinib with primary endpoint to improve PFS from 4 to 8 months (El-Khoueiry et al., 2012b). Two patients had a PR and 8 had SD as their best response, but there were 3 deaths while on study with one possibly related to treatment. The mPFS/OS was 2 and 6 months and the trial was stopped early due to a weak efficacy signal. Further studies are required to assess whether there may be benefit in certain subsets of patients.
God bless.

Holly…a few years back, Avastin was hailed the new wonder drug targeting numerous cancers however; subsequent studies disproved that theory. Well, it curbed the efficacy time significantly and the side effect of possible perforation was noted. This may explain the issue of the older lost links referring to this drug, as in recent years we have not witnessed much use of Avastin in treatment of our cancer.
My two cents.
Hugs,
Marion

http://www.cholangiocarcinoma.org/punbb/viewtopic.php?pid=57198#p57198Hi,Holly,

How are you?

”11.Erlotinib+bevacizumab regimen:(pt pop=53,43 had CCA the rest were gallbaladder);9 had partial response and 51 patients had stable responses.
grade 3-4 cerebral thrombosis or low blood flow(ischemia)and rash.’

the above is from

http://www.cholangiocarcinoma.org/punbb/viewtopic.php?pid=57198#p57198.

You can look over each drug and combine them to know more about their effcacy and adverse reactions.

One Caution: if you have diverticulitis ,and related colon problems,then make sure talk to your oncologist;each drug has the same side effect but combine together, the risk should not be take it lightly. My sis-in-law who passed away had just one – three doses of Avastin at the most, and she perforated her colon.
God Bless.

Hi Jason,

Many thanks for pointing that out and I get the same message when I click on the link too, very weird!

Try this link and see if that one works, hopefully!

http://www.cholangiocarcinoma.org/punbb/search.php?search_id=752242255

Best wishes,

Gavin

Hi Holly~ Fancy meeting you here! Did you find any more information as to people’s experiences with this combo? FOLFIRI seems not to be working for me, so we have to come up with a new plan. A MEK trial is one option, Tarceva/Avastin another. I don’t know what else. Our doc chuckles because we seem to be presenting her with the same questions about other agents. Maybe we can discuss.

I hope you are doing well.
Regina (Serena)